Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: j_fir2 who wrote (1971)	3/9/1999 2:09:00 PM
From: David Howe	Read Replies (1) \| Respond to of 10280

It will be Lilly, JNJ and the other big pharmas that have to fight a battle with the FTC if there is one. It will probably be as simple as showing them that the ICEs are new improved products, not a new patent of the same drug. It's the big pharmas that can lose something here. This can be viewed as validating the worth of SEPR's strategy, because it's obvious that the big pharmas need SEPR in order to preserve their drug franchises. Dave